We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fully Automated Blood-Based Assays Measure Biomarker for Neurodegenerative Diseases within 35 Minutes

By LabMedica International staff writers
Posted on 29 Mar 2023
Print article
Image: Fujirebio has launched the fully automated Lumipulse G NfL CSF and Lumipulse G NfL blood tests (Photo courtesy of Fujirebio)
Image: Fujirebio has launched the fully automated Lumipulse G NfL CSF and Lumipulse G NfL blood tests (Photo courtesy of Fujirebio)

Neurofilament light (NfL) is considered to be a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies in conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as in acute situations like traumatic brain injury (TBI). Now, researchers and clinical research professionals across the world can further study the clinical utility of this promising biomarker by using newly-launched biomarker tests that enable the quantitative measurement of NfL.

Fujirebio (Gent, Belgium) has expanded its assay menu in the field of neurodegenerative diseases by launching the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood CLEIA (chemiluminescent enzyme immunoassay) assays for the LUMIPULSE G immunoassay systems. The assays enable the quantitative measurement of NfL in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, in only 35 minutes. The assays are available for Research Use Only and will allow researchers and clinical research professionals to further examine the clinical utility of NfL in diverse disease conditions like multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as TBI.

Laboratory professionals can opt for their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardized immunoassay system family is widely available and used by routine labs which are active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform fulfills the required throughput, quality, and regulatory requirements for supporting potential future routine use of NfL apart from the existing portfolio.

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” said Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative disease field as quickly as possible.”

Related Links:

Unit-Dose Twist-Tip BFS
Platinum Supplier
Diagnostic Reader
Acucy System
Automated Chemistry Analyzer
TC-Matrix 600
Platinum Supplier
Ultra-Low PSA Control
Prostate-Specific Antigen Control

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The T2Biothreat Panel runs on the T2Dx Instrument (Photo courtesy of T2 Biosystems)

Fully-Automated, Direct-From-Blood Test Rapidly Detects Multiple Biothreat Pathogens

During a public health emergency involving biothreat pathogens, rapid and accurate diagnostic testing is vital for reducing health and economic consequences. Infections by these pathogens, if not promptly... Read more


view channel
Image: navify digital solutions can helping labs mitigate unique quality challenges (Photo courtesy of Roche)

Cloud-Based Digital Solution Allows Labs to Track Test Samples along Entire Diagnostic Journey

Diagnosing a disease involves a meticulous procedure of monitoring a patient's diagnostic sample throughout its entire journey, which aids in clinical decision-making. However, there aren't any standardized... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.